InnoCare Pharma (09969) reported net profit attributable to shareholders of approximately RMB656 million for the first three quarters, turning profitable year-on-year.

InnoCare Pharma (09969) announced its results for the first three quarters of 2026. Total operating revenue was RMB2.099 billion, up 88.21% year-on-year, of which pharmaceutical sales revenue was RMB1.449 billion, up 41.47% year-on-year. The growth in operating revenue was mainly due to the continued volume ramp-up of the core product orelabrutinib, the incremental sales contribution from tafasitamab and zurletrectinib, and the completion of subsequent milestone deliveries under the company's licensing agreement with Zenas BioPharma, Inc. Net profit attributable to shareholders of the listed company was approximately RMB656 million, turning profitable year-on-year. From January to September 2026, net cash flow from operating activities was RMB220 million, turning positive from negative year-on-year, mainly benefiting from increased pharmaceutical sales and licensing revenue, as the company's operating cash flow position continued to improve.